Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908049324> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2908049324 abstract "Objective: Psoriatic arthritis is an autoimmune disease. The marketed drugs cannot totally cure the disease state as well as they have severe side effects and for that reason researcher and scientists are going for traditional medicines. Costus speciosus is the plant of choice for its several positive activities against psoriatic arthritis.Methods: Wistar albino healthy rat was taken for 0.1 ml of Freund adjuvant-induced anti-arthritic and anti-inflammatory test, and diclofenac sodium (15 mg/kg) was taken as standard drug. The paw volume was measured at different time 1st, 7th, 14th, and 21st days of experiment. In another study, the protocol is same, but indomethacin (10 mg/kg) was taken as standard drug. Another study was performed to know that the plant drug has any lipopolysaccharide (LPS)-stimulated COX-protein inhibitor activity or not. An acute anti-inflammatory property was studied in carrageenan-induced paw edema and result is measured by plethysmometer. The chronic anti-inflammatory property was studied by cotton pellet-induced granuloma formation. 400 mg/kg and 800 mg/kg dose of ethanolic extract is administered to the animal of both acute and chronic studies.Results: In anti-arthritic and anti-inflammatory study, after the 21st day, it has found that standard drug (diclofenac sodium) decreases paw volume 40 % where the plant drug reduces it 68.33% & 75.50% at higher and lower dose respectively. In the other study the Standard drug (Indomethacin) show arthritic score of 0.83 and the extract shows 1.67 at its higher concentration. In LPS-stimulated cyclooxygenase-2 (COX-2) inhibition study, extract helps to decrease the LPS-stimulated COX-2 protein nearly similar as methotrexate without any side effect. In the cotton pallet-induced anti-inflammatory study, 400 mg/kg and 800 mg/kg dose of ethanolic extract shows similar result against standard drug.Conclusion: Although its activity is less compared to the marketed drug, in the other sides, it has very mild adverse effect compared to the marketed Drug. It can be used as a supportive drug in the treatment of Psoriatic arthritis and by chemical modification the activity may be increased without any side effect." @default.
- W2908049324 created "2019-01-11" @default.
- W2908049324 creator A5020623593 @default.
- W2908049324 creator A5042753296 @default.
- W2908049324 date "2019-01-07" @default.
- W2908049324 modified "2023-09-26" @default.
- W2908049324 title "COSTUS SPECIOSUS AND ITS ANTIPSORIATIC ARTHRITIS ACTIVITY: A REVIEW" @default.
- W2908049324 doi "https://doi.org/10.22159/ajpcr.2019.v12i1.20430" @default.
- W2908049324 hasPublicationYear "2019" @default.
- W2908049324 type Work @default.
- W2908049324 sameAs 2908049324 @default.
- W2908049324 citedByCount "0" @default.
- W2908049324 crossrefType "journal-article" @default.
- W2908049324 hasAuthorship W2908049324A5020623593 @default.
- W2908049324 hasAuthorship W2908049324A5042753296 @default.
- W2908049324 hasBestOaLocation W29080493241 @default.
- W2908049324 hasConcept C116263406 @default.
- W2908049324 hasConcept C126322002 @default.
- W2908049324 hasConcept C203014093 @default.
- W2908049324 hasConcept C2776260265 @default.
- W2908049324 hasConcept C2777077863 @default.
- W2908049324 hasConcept C2777863537 @default.
- W2908049324 hasConcept C2779703632 @default.
- W2908049324 hasConcept C2779826273 @default.
- W2908049324 hasConcept C2780035454 @default.
- W2908049324 hasConcept C2780564577 @default.
- W2908049324 hasConcept C2780886150 @default.
- W2908049324 hasConcept C2781227287 @default.
- W2908049324 hasConcept C2908765736 @default.
- W2908049324 hasConcept C29730261 @default.
- W2908049324 hasConcept C556039675 @default.
- W2908049324 hasConcept C71924100 @default.
- W2908049324 hasConcept C98274493 @default.
- W2908049324 hasConceptScore W2908049324C116263406 @default.
- W2908049324 hasConceptScore W2908049324C126322002 @default.
- W2908049324 hasConceptScore W2908049324C203014093 @default.
- W2908049324 hasConceptScore W2908049324C2776260265 @default.
- W2908049324 hasConceptScore W2908049324C2777077863 @default.
- W2908049324 hasConceptScore W2908049324C2777863537 @default.
- W2908049324 hasConceptScore W2908049324C2779703632 @default.
- W2908049324 hasConceptScore W2908049324C2779826273 @default.
- W2908049324 hasConceptScore W2908049324C2780035454 @default.
- W2908049324 hasConceptScore W2908049324C2780564577 @default.
- W2908049324 hasConceptScore W2908049324C2780886150 @default.
- W2908049324 hasConceptScore W2908049324C2781227287 @default.
- W2908049324 hasConceptScore W2908049324C2908765736 @default.
- W2908049324 hasConceptScore W2908049324C29730261 @default.
- W2908049324 hasConceptScore W2908049324C556039675 @default.
- W2908049324 hasConceptScore W2908049324C71924100 @default.
- W2908049324 hasConceptScore W2908049324C98274493 @default.
- W2908049324 hasLocation W29080493241 @default.
- W2908049324 hasOpenAccess W2908049324 @default.
- W2908049324 hasPrimaryLocation W29080493241 @default.
- W2908049324 hasRelatedWork W2014207475 @default.
- W2908049324 hasRelatedWork W2045103801 @default.
- W2908049324 hasRelatedWork W2062806566 @default.
- W2908049324 hasRelatedWork W2158409050 @default.
- W2908049324 hasRelatedWork W2767266810 @default.
- W2908049324 hasRelatedWork W2908049324 @default.
- W2908049324 hasRelatedWork W4200192277 @default.
- W2908049324 hasRelatedWork W4206236667 @default.
- W2908049324 hasRelatedWork W4237161692 @default.
- W2908049324 hasRelatedWork W2034889580 @default.
- W2908049324 isParatext "false" @default.
- W2908049324 isRetracted "false" @default.
- W2908049324 magId "2908049324" @default.
- W2908049324 workType "article" @default.